drugset
Drugs / D-1553
last change Jul 2026 re-read 2 minutes ago

D-1553

also known as garsorasib

targets KRAS via inhibition

Developed for
non-small cell lung carcinoma · cancer · neoplasm
Investigated by
InventisBio Co., Ltd · InxMed (Shanghai) Co., Ltd. · Suzhou Genhouse Bio Co., Ltd. · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Merck Sharp & Dohme LLC · Zhejiang Cancer Hospital

Trials 11 · a red edge is where a trial was stopped

today NCT07318649 · Ph 2 NCT07174908 · Ph 3 NCT06435455 · Ph 1/2 NCT06300177 · Ph 3 NCT06233916 · Ph 1 NCT06105255 · Ph 1 NCT06166836 · Ph 1/2 NCT05379946 · Ph 1/2 NCT05492045 · Ph 1/2 NCT05383898 · Ph 1/2 NCT04585035 · Ph 1/2
20212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06233916 Dec 2023 → Jan 2024 — InventisBio Co., Ltd Completed No outcome recorded
Phase 1 NCT06105255 May 2023 → Feb 2024 — InventisBio Co., Ltd Completed No outcome recorded
Phase 1/26 trials
Phase 1/2 NCT06435455 Jul 2024 → Sep 2027 expected — Suzhou Genhouse Bio Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT06166836 Oct 2022 → Dec 2027 expected neoplasm InxMed (Shanghai) Co., Ltd. Active not recruiting No outcome recorded
Phase 1/2 NCT05379946 Oct 2022 → Dec 2027 expected cancer InventisBio Co., Ltd Active not recruiting No outcome recorded
Phase 1/2 NCT05492045 Sep 2022 → Jun 2024 non-small cell lung carcinoma InventisBio Co., Ltd Terminated No outcome recorded
Phase 1/2 NCT05383898 Mar 2021 → Nov 2023 non-small cell lung carcinoma InventisBio Co., Ltd Completed No outcome recorded
Phase 1/2 NCT04585035 Oct 2020 → Apr 2024 overdue non-small cell lung carcinoma InventisBio Co., Ltd Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07318649 Dec 2025 → Dec 2026 expected — Suzhou Genhouse Bio Co., Ltd. Not yet recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT07174908 Sep 2025 → Sep 2028 expected non-small cell lung carcinoma InxMed (Shanghai) Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT06300177 Mar 2024 → Oct 2026 expected non-small cell lung carcinoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as D-1553 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04585035 ↗
10

NCT06233916 ↗

NCT06300177 ↗

NCT06166836 ↗

NCT06435455 ↗

NCT05383898 ↗

NCT05379946 ↗

NCT06105255 ↗

NCT07174908 ↗

NCT05492045 ↗

NCT07318649 ↗
Known as garsorasib “Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor, has demonstrated promising anti-tumor activity and favorable safety profile in early clinical trials.” PMID 40523897 ↗ Jun 2025
2

“Garsorasib is a novel KRASG12C inhibitor approved in China for patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC).” PMID 42413526 ↗ Jul 2026

“D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor.” PMID 36948246 ↗ Mar 2023
Action Inhibit “Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor” PMID 40523897 ↗ Jun 2025
Route Oral “potential oral agent” NCT04585035 ↗
Target KRAS “Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor” PMID 40523897 ↗ Jun 2025